Cosentyx SensoReady® 150mg pen self injection video


Cosentyx UnoReady® 300mg pen self injection video

Rate this content: 
No votes yet
IE271483 | March 2023

Reporting of side effects
Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: Adverse events could also be reported to Novartis preferably via or by email: [email protected] or by calling 01 2080 612.


Ask Speakers


Medical Information Request